Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Page 1
Long-COVID cognitive impairments and reproductive hormone deficits in men may stem from GnRH neuronal death.
Sauve F, Nampoothiri S, Clarke SA, Fernandois D, Ferreira Coêlho CF, Dewisme J, Mills EG, Ternier G, Cotellessa L, Iglesias-Garcia C, Mueller-Fielitz H, Lebouvier T, Perbet R, Florent V, Baroncini M, Sharif A, Ereño-Orbea J, Mercado-Gómez M, Palazon A, Mattot V, Pasquier F, Catteau-Jonard S, Martinez-Chantar M, Hrabovszky E, Jourdain M, Deplanque D, Morelli A, Guarnieri G, Storme L, Robil C, Trottein F, Nogueiras R, Schwaninger M, Pigny P, Poissy J, Chachlaki K, Maurage CA, Giacobini P, Dhillo W, Rasika S, Prevot V. Sauve F, et al. Among authors: pasquier f. EBioMedicine. 2023 Oct;96:104784. doi: 10.1016/j.ebiom.2023.104784. Epub 2023 Sep 13. EBioMedicine. 2023. PMID: 37713808 Free PMC article.
Olfactory and cognitive alterations, which persist in some COVID-19 patients, and long-term hypotestosteronaemia in SARS-CoV-2-infected men are also reminiscent of the consequences of deficient GnRH, suggesting that GnRH system neuroinvasion could underlie certain post-COV …
Olfactory and cognitive alterations, which persist in some COVID-19 patients, and long-term hypotestosteronaemia in SARS-CoV-2-infect …
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.
Saleh K, Fernandez A, Pasquier F. Saleh K, et al. Among authors: pasquier f. Cancers (Basel). 2022 Apr 1;14(7):1805. doi: 10.3390/cancers14071805. Cancers (Basel). 2022. PMID: 35406576 Free PMC article. Review.
Ph+ ALL patients traditionally had dismal prognosis and long-term survivors were only observed among patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). ...
Ph+ ALL patients traditionally had dismal prognosis and long-term survivors were only observed among patients who underwent allogenei …
Telemedicine in French Memory Clinics During the COVID-19 Pandemic.
Morin A, Pressat-Laffouilhere T, Sarazin M, Lagarde J, Roue-Jagot C, Olivieri P, Paquet C, Cognat E, Dumurgier J, Pasquier F, Lebouvier T, Ceccaldi M, Godefroy O, Martinaud O, Grosjean J, Zarea A, Maltête D, Wallon D. Morin A, et al. Among authors: pasquier f. J Alzheimers Dis. 2022;86(2):525-530. doi: 10.3233/JAD-215459. J Alzheimers Dis. 2022. PMID: 34974434
Telemedicine consultations allowed treatment modifications with only a minor short-term negative impact on therapeutic strategies....
Telemedicine consultations allowed treatment modifications with only a minor short-term negative impact on therapeutic strategies....
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M, Hermange G, Tisserand A, Noble R, Marzac C, Marty C, Le Sueur C, Campario H, Vertenoeil G, El-Khoury M, Catelain C, Rameau P, Gella C, Lenglet J, Casadevall N, Favier R, Solary E, Cassinat B, Kiladjian JJ, Constantinescu SN, Pasquier F, Hochberg ME, Raslova H, Villeval JL, Girodon F, Vainchenker W, Cournède PH, Plo I. Mosca M, et al. Among authors: pasquier f. Blood. 2021 Dec 2;138(22):2231-2243. doi: 10.1182/blood.2021010986. Blood. 2021. PMID: 34407546 Free PMC article.
To determine factors that influence molecular response rate, we evaluated the long-term molecular efficacy of IFNalpha in patients with MPN by monitoring the fate of cells carrying driver mutations in a prospective observational and longitudinal study of 48 patients over m …
To determine factors that influence molecular response rate, we evaluated the long-term molecular efficacy of IFNalpha in patients wi …
Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD.
Dyer AH, Murphy C, Lawlor B, Kennelly SP; NILVAD Study Group. Dyer AH, et al. J Am Med Dir Assoc. 2020 Feb;21(2):194-200. doi: 10.1016/j.jamda.2019.08.006. Epub 2019 Oct 8. J Am Med Dir Assoc. 2020. PMID: 31604674 Clinical Trial.
Cognition was measured at baseline and 18 months using the Alzheimer Disease Assessment Scale, Cognitive Subsection (ADAS-Cog). We assessed predictors of long-term BDZR use and analyzed the effect of ongoing BDZR use on ADAS-Cog scores at 18 months. ...
Cognition was measured at baseline and 18 months using the Alzheimer Disease Assessment Scale, Cognitive Subsection (ADAS-Cog). We assessed …
ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease.
Letronne F, Laumet G, Ayral AM, Chapuis J, Demiautte F, Laga M, Vandenberghe ME, Malmanche N, Leroux F, Eysert F, Sottejeau Y, Chami L, Flaig A, Bauer C, Dourlen P, Lesaffre M, Delay C, Huot L, Dumont J, Werkmeister E, Lafont F, Mendes T, Hansmannel F, Dermaut B, Deprez B, Hérard AS, Dhenain M, Souedet N, Pasquier F, Tulasne D, Berr C, Hauw JJ, Lemoine Y, Amouyel P, Mann D, Déprez R, Checler F, Hot D, Delzescaux T, Gevaert K, Lambert JC. Letronne F, et al. Among authors: pasquier f. EBioMedicine. 2016 Jul;9:278-292. doi: 10.1016/j.ebiom.2016.06.002. Epub 2016 Jun 2. EBioMedicine. 2016. PMID: 27333034 Free PMC article.
Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered Abeta42 secretion in neuron primary cultures, soluble Abeta42 and amyloid plaque load levels in the brain and concomitantly enhanced CTSD activity and finally rescued long term potentia …
Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered Abeta42 secretion in neuron primary cultures, solubl …
Multiple Simultaneous Spontaneous Intracerebral Hemorrhages: A Rare Entity.
Chen Y, Hénon H, Bombois S, Pasquier F, Cordonnier C. Chen Y, et al. Among authors: pasquier f. Cerebrovasc Dis. 2016;41(1-2):74-9. doi: 10.1159/000442475. Epub 2015 Dec 16. Cerebrovasc Dis. 2016. PMID: 26671248
BACKGROUND: In hospital databases, multiple simultaneous spontaneous intracerebral hemorrhages (ICH-m) account for 0.7-5.6% of all ICHs. Their long-term outcome has never been systematically and prospectively investigated. We aimed at identifying the long-term outco …
BACKGROUND: In hospital databases, multiple simultaneous spontaneous intracerebral hemorrhages (ICH-m) account for 0.7-5.6% of all ICHs. The …
Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761.
Scherrer B, Andrieu S, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Vellas B. Scherrer B, et al. Among authors: pasquier f. J Nutr Health Aging. 2015 Dec;19(10):1009-11. doi: 10.1007/s12603-015-0661-2. J Nutr Health Aging. 2015. PMID: 26624212 Free article. Clinical Trial.
This post hoc analysis illustrates the interest of performing another randomised clinical trial of EGb761 explicitly testing the hypothesis of a late treatment effect, as well as of using of better adapted statistical approaches for long term preventive trials when it is e …
This post hoc analysis illustrates the interest of performing another randomised clinical trial of EGb761 explicitly testing the hypothesis …
Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial.
Amieva H, Robert PH, Grandoulier AS, Meillon C, De Rotrou J, Andrieu S, Berr C, Desgranges B, Dubois B, Girtanner C, Joël ME, Lavallart B, Nourhashemi F, Pasquier F, Rainfray M, Touchon J, Chêne G, Dartigues JF. Amieva H, et al. Among authors: pasquier f. Int Psychogeriatr. 2016 May;28(5):707-17. doi: 10.1017/S1041610215001830. Epub 2015 Nov 17. Int Psychogeriatr. 2016. PMID: 26572551 Clinical Trial.
BACKGROUND: Although non-drug interventions are widely used in patients with Alzheimer's disease, few large scale randomized trials involving a long-term intervention and several cognitive-oriented approaches have been carried out. ...
BACKGROUND: Although non-drug interventions are widely used in patients with Alzheimer's disease, few large scale randomized trials involvin …
A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. Lovestone S, et al. J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959. J Alzheimers Dis. 2015. PMID: 25537011 Clinical Trial.
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced n …
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, …
29 results